Bloomberg Law
Feb. 3, 2022, 10:35 AMUpdated: Feb. 3, 2022, 2:52 PM

Fast Drug Approvals to Get Lawmaker Focus in FDA Fee Plan Review (1)

Celine Castronuovo
Celine Castronuovo

Lawmakers will likely focus on FDA staffing woes and speedy drug approvals as they kick off the first of a series of hearings on must-pass legislation to renew the fees that help fund the agency.

A Thursday hearing of the House Commerce Committee’s health panel begins the congressional review process for the next round of user fee agreements between the FDA and the prescription drug, generic drug, and biosimilar industries. Congress must pass laws adopting the new deals for fiscal years 2023 through 2027, before the current agreements expire Sept. 30.

The user fee deals, which also contain agency commitments ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.